Scribe Therapeutics Verifies In Vivo CRISPR-Based Cardiometabolic Therapies
Inside Precision Medicine
|
November 27, 2024
X min read
Inside Precision Medicine
|
November 27, 2024
Share on Social
More like this
News
Scribe Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 9, 2025
Read Now
Press
Scribe Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 9, 2025
Read Now
News
From The Lab To The Clinic: Developing And Delivering The Next Generation Of Therapies To Patients In Need
December 6, 2024
Forbes Healthcare Summit
Read Now
Press
From The Lab To The Clinic: Developing And Delivering The Next Generation Of Therapies To Patients In Need
December 6, 2024
Forbes Healthcare Summit
Read Now
News
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Read Now
Press
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Read Now
